On Invalid Date, Homology Medicines (NASDAQ: FIXX) reported Q1 2022 earnings per share (EPS) of $1.61, up 8,150% year over year. Total Homology Medicines earnings for the quarter were $92.11 million. In the same quarter last year, Homology Medicines's earnings per share (EPS) was -$0.02.
As of Q3 2022, Homology Medicines's earnings has grown year over year. Homology Medicines's earnings in the past year totalled -$2.59 million.
What was FIXX's revenue last quarter?
On Invalid Date, Homology Medicines (NASDAQ: FIXX) reported Q1 2022 revenue of $802.00 thousand up 97.26% year over year. In the same quarter last year, Homology Medicines's revenue was $29.31 million.
What was FIXX's revenue growth in the past year?
As of Q3 2022, Homology Medicines's revenue has grown -82.6% year over year. This is 1,109.45 percentage points lower than the US Biotechnology industry revenue growth rate of 1,026.85%. Homology Medicines's revenue in the past year totalled $5.47 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.